Creative Financial Designs’s Artelo Biosciences ARTL Stock Holding History

Creative Financial Designs’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$167	–	1473
2023 Q1	$167	Hold	4	–	–	﹤0.01%	1372
2022 Q4	$208	Hold	4	–	–	﹤0.01%	1272
2022 Q3	$0	Hold	4	–	–	﹤0.01%	1274
2022 Q2	$0	Hold	4	–	–	﹤0.01%	1236
2022 Q1	$0	Hold	4	–	–	﹤0.01%	1252
2021 Q4	$1K	Buy	+4	New	+$790	﹤0.01%	1152

Other funds holding ARTL

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Creative Financial Designs's ARTL Position: Q2 2023 in Review

Creative Financial Designs sold out of Artelo Biosciences (ARTL) in Q2 2023, closing a stake of 4 shares — an estimated $167 sold.

Creative Financial Designs first reported a position in ARTL in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q4 2021. 6 funds tracked by Wall St. Rank hold ARTL as of Q2 2023.

Creative Financial Designs reported no remaining Artelo Biosciences position as of Q2 2023 after selling out during the quarter.
Creative Financial Designs sold 4 Artelo Biosciences shares in Q2 2023, an estimated $167.
Creative Financial Designs first reported a position in Artelo Biosciences in Q4 2021 and held it in 6 quarters.
Creative Financial Designs's Artelo Biosciences position peaked at $1K in Q4 2021.
6 funds tracked by Wall St. Rank held Artelo Biosciences as of Q2 2023.

Based on Creative Financial Designs's 13F filing for Q2 2023, filed 26 Jul 2023.